A Phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of flexible dosing of brexpiprazole (OPC-34712) in the treatment of subjects with agitation associated with dementia of the Alzheimer's type

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer\'s type
Epistemonikos ID: 39596b6df4f2dfcfeadb81a008970f3487721cef
First added on: May 11, 2024